Autoimmune haemolytic anaemia
Immune system and Malignant Disease
Rituximab is recommended as an alternative treatment for adults with AIHA where patients are contraindicated to or fail to respond to standard active treatments (e.g. corticosteroids).
Treatment requires initiation and continuation by specialist haematology services.
Reason for decision: